PARKINSON AND STEM CELL THERAPY
Keywords:
parkinson, stem cell, neurodegeneratifAbstract
Parkinson's disease is a neurodegenerative disorder that is progressive about the movement or control of movement. The disease often occurs in people over the age of 60 years. The etiology of Parkinson's disease caused by a combination of genetic and environmental factors. Because overall life expectancy increases, the number of people with Parkinson's disease will increase in the future. Treatment of Parkinson's disease can be used with pharmacological therapy and nonpharmacological therapy. Pharmacological therapy can use levodopa, monoamine oxidase-B inhibitors, dopamine agonists, anticholinergics and amantadine, while nonpharmacological therapies may use the method of stem cell therapy. Stem cells are master cells that have two important characteristics that can perform self-renewing through cell division and can be induced to become cells with specific functions. The aim of Stem cell therapy in Parkinson's disease to replace the damaged dopaminergic cells.
References
Koutoudis, Ted K. Parkinson’s Disease (http://www.emedicinehealth.com/parkinson_disease/article_em.htm 2010. Diakses tanggal 6 Juni 2013).
Cheryl HW.Diagnosis and Management Parkinsons Disease. Profesional Communication Inc, 1999.
Heyne, Sietske N. Parkinson’s Disease (http://www.medicinenet.com/parkinsons_disease/article.htm, 2010. Diakses tanggal 7 Juni 2013).
Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of Parkinson’s disease. CMAJ 2003;168(3):293301.
Clinton S. Understanding Stem Cells. Diakses dari http://www.national-academies.org tanggal 10 Agustus 2013. 2005.
Moghal S, Rajput AH, D’Arcy C, Rajput R. Prevalence of movement disorders in elderly community residents. Neuroepidemology, 1994;13:175-178.
Hauser RA, Lyons KE. Parkinson Disease Questions and Answer.USA,Merit Publishing International 2003:49-59.
Perkin GD. An atlas of Parkinson’s disease and related disorders.The Encyclopedia of Visual Medicine Series. London: CRC Press LLC. 2004.
Samuels AM. Manual of Neurologi Therapeutics. Philadeplhia: Lippincott Williams & Walkins. 2004.
John CM, Brust MD. Current Diagnosis & Treatment in Neurology. McGraw-Hill Professional. 2007.
Weintraub D, Cornella CL, Horn S. Parkinson disease –part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care. 2008;14:S40-S48.
Louis A, Brad KL. Understanding Stem Cells. 2005. Diakses dari http://www.nationalacademies.org tanggal 10 Agustus 2013.
Houdin J. Stem Cell Research and Parkinson’s Disease. 2009. Diakses dari http://www.parkinson.ca tanggal 10 Agustus 2013.
Prakash S. Artificial cells, cell engineering and therapy. Cambridge England: Woodhead Publishing Limited. 2007.
Taupin P. The Therapeutic Potential of Adult Neural Stem Cells.In: Stem Cells. New York: Nova Science Publishers, Inc. 2009. p.119-127
Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 2004.318:121–134.
Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S. 2001. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 344:710–719.
Paul G. Cell transplantation for patients with Parkinson’s disease. In: Stem Cells. Handbook of Experimental Pharmacology Volume 174. Germany: Springer-Verlag Berlin Heidelberg. 2006. Page 362-380.
Brundin P, Hagell P. The neurobiology of cell transplantation in Parkinsons’s disease. Clin Neurosci Res. 2001. 1:507–520.
Vawda R, Kennea NL, Mehmet H. Stem cell in Neurodegeneration and Injury. New York: Taylor and Francis Group. 2006. Page 272286.
Rahayu M, Kurniawan SN, Husna M, Hermawan HO. The Effect of Beta Glucan of Saccharomyces Cerevisae on the Decrease of Alpha Synuclein Expression in the Brain Substantia Nigra of Parkinson’s Wistar Strain Rats (Rattus novergicus) Model Induced with Rotenone. Malang Neurology Journal. 2016 Jan 1;2(1):8-12.
